Novo Nordisk A/S NVO

Key data

The business

Novo Nordisk sells one molecule, semaglutide, under three names. Ozempic and Rybelsus treat type-2 diabetes, and Wegovy treats obesity. All of it is the same active drug that tells the body it is full and slows the gut, delivered as a once-weekly pen injection and, since this year, as a pill. Around this sits a smaller, older insulin business and a rare-disease unit. A patient picks up a prefilled pen at the pharmacy each month, or now swallows a tablet, and the prescription refills for years, because stopping means the weight comes back.

The moat is manufacturing and biology, not brand. Making injectable peptides at this scale takes years of plant construction a new entrant cannot buy off a shelf, and Novo and Lilly are the only two who have done it. That is also the vulnerability: it is a two-horse race, switching costs for the patient are low, and the second horse is running faster right now.

The numbers

Novo reports in Danish kroner and files a light 6-K, so a clean five-quarter series is not in the machine-readable record, and the two 2026 halves, derived from the H1 filing, carry the recent shape.

DKK billions. Q1 looks enormous and Q2 looks broken, and both are optical: a US 340B rebate reversal loaded revenue and profit into Q1, while a matching reversal back in Q2 2025 made this quarter's comparison brutal, printing net profit down 21%. Strip the noise and adjusted operating profit still grew 8% in the quarter. The real signal sits lower down: growth has slowed from a 30%-plus company to a single-digit one.

DKK billions. From 2021 to 2024 revenue compounded 27% a year and net income kept pace, one of the great runs in large-cap pharma. Then the wall: 2025 revenue grew 6% and net income 1.4%. Over the same stretch capital spending went from DKK 6.3B to DKK 60.1B, a quarter of every sales krone, poured into new plants on the belief that volume keeps climbing. Returns on money already invested stay elite, near 59% on equity and 30% on capital, but free cash flow has thinned as the concrete goes up. The market has drawn its own conclusion: consensus sees 2028 earnings roughly flat with today, which is why the stock costs slightly more against next year's profit than last year's, a rare inversion that says melting franchise, not growth.

DKK billions, growth at constant rates. The obesity line still grows 16%, but almost all of that now comes from the new Wegovy pill, because the injectable that built the franchise has stalled at 1%. That one number is the whole argument: either the pill and price cuts reignite it, or Lilly has taken the momentum for keeps.

Management

Maziar Mike Doustdar became CEO in 2025, brought in during the slide that has left the stock down more than a quarter from its 52-week high. There were no open-market insider buys or sells in the window, unsurprising for a Danish issuer whose Form 4 trail is thin, so read intent from capital return instead: DKK 41.2B went back to owners in the first half, DKK 35.3B as dividends and DKK 5.9B as buybacks, and a fresh repurchase programme has run weekly under EU safe-harbour rules since 6 May. Buying stock at 11 times earnings is the right moment to do it. Whether it beats spending that cash against DKK 60B of annual plant is the open question. Pay against profit is not disclosed in this record.

How it fails or surprises you

Lilly takes obesity for good. Zepbound and Mounjaro are compounding while Wegovy's injectable sits at 1%, and Lilly's own oral drug is close behind. If Wegovy stays flat for two more quarters while Lilly grows 30%, Novo slips from first to a clear second, and 11x earnings stops being a floor and becomes a value trap. Watch Wegovy constant-currency growth and US prescription share.

The plants outrun the volume. Q2 operating margin fell to 34.5%, and even adjusted, profit grew 8% while capital spending ran at 25% of sales. Novo is building capacity for volumes it does not yet have. If scripts fail to fill DKK 60B of new plant, margins keep sliding and the spend becomes stranded concrete. Watch operating margin against capex-to-sales.

The pill cracks the market open (right tail). The Wegovy pill added DKK 3.2B in its first partial quarter with nothing to compare against, and an oral drug removes the needle that stops most of the world's overweight from ever starting. If oral semaglutide scales through 2027, Novo re-rates from 11x back toward the 21-to-31x band it held for a decade. Watch oral obesity sales into next year.

Closing thoughts

The market has priced flat earnings to 2028, visible in that inverted multiple where next year's profit costs more than last year's. Whether that's right hinges entirely on Wegovy's constant-currency growth over the next two quarters. Reaccelerate into double digits and the flat assumption breaks and the stock is badly mispriced. Stall again near 1% and Lilly has won and the cheapness is deserved. The left tail, a franchise that erodes to number two, is real and permanent. The right tail, an oral drug that doubles the addressable market, is worth several times the downside.

The bet is still that hundreds of millions of people who could take a weight-loss drug keep choosing Wegovy and Ozempic, and that Novo holds its lead by moving from a weekly shot to a pill people can simply swallow. What breaks it is one pair of numbers, Wegovy's growth against Lilly's, quarter after quarter. If the injectable is still stuck at low single digits when the pill's easy comparisons run out in mid-2027, the bet is wrong no matter how cheap it looked getting there.